APC

(redirected from Adenomatous polyposis coli)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Adenomatous polyposis coli: Familial adenomatous polyposis

APC

(cell and molecular biology)
(electronics)

APC

On drawings, abbr. for “acoustical plaster ceiling.”

APC

APC

(1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. Although created to develop solar electricity, the company introduced its first UPS system three years later as government funding for solar energy dissipated.

(2) (Application Performance Characterization) A graphics benchmark that tests actual application performance. See GPC.
References in periodicals archive ?
Familial Adenomatous Polyposis Coli - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
We obtained DNA samples from patients with attenuated or classic adenomatous polyposis coli and no detectable APC germline mutations.
Global Markets Direct's, 'Familial Adenomatous Polyposis Coli - Pipeline Review, Q2 2011', provides an overview of the Familial Adenomatous Polyposis Coli therapeutic pipeline.
In colon cancer, excessive cell growth occurs as the result of the accumulation of a regulatory protein, beta-catenin, usually caused by mutations in the adenomatous polyposis coli (APC) gene.
In colon cancer, excessive cell growth occurs as the result of the accumulation of a regulatory protein, beta-catenin, caused by mutations in the adenomatous polyposis coli (APC) gene.
The company recently filed a New Drug Application for its lead SAANDs compound, Aptosyn(TM) (exisulind) for the regression and chemoprevention of adenomatous polyposis coli (APC).
The company is seeking marketing approval of Aptosyn for the treatment of adenomatous polyposis coli ("APC"), a rare disease that puts those afflicted at high risk of developing colon cancer.
Nasdaq:CLPA) today announced that it had concluded the evaluation of the Phase III trial of its lead investigational drug, exisulind, in adenomatous polyposis coli ("APC").
As previously announced, the Company is continuing to evaluate the data from its Phase III clinical trial of exisulind for the indication of adenomatous polyposis coli.
Nasdaq:CLPA) today announced that it had initiated an open label Phase II efficacy study of its lead investigational drug (exisilund) as a treatment for precancerous colon polyps in children with adenomatous polyposis coli (APC).